Navigation Links
NeurogesX to Hold Conference Call to Discuss Third Quarter 2010 Results
Date:10/28/2010

SAN MATEO, Calif., Oct. 28 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced it will hold a conference call on Wednesday, November 3, 2010 at 8:30 a.m. EDT (5:30 a.m. PDT) to report results for its third quarter ended September 30, 2010.

The conference call will be hosted by Anthony DiTonno, President and Chief Executive Officer, and Stephen Ghiglieri, Executive Vice President, Chief Operating Officer and Chief Financial Officer.

To participate, please dial 1-877-407-0789 (USA) or 1-201-689-8562 (International).  To access the live web cast please visit the Investor Relations section on the corporate web site at http://www.neurogesx.com.

A replay of the conference call will be available beginning November 3, 2010 at 11:30 a.m. EDT (8:30 a.m. PDT) and ending on November 13, 2010 by dialing 1-877-870-5176 (USA) or 1-858-384-5517 (International) with Conference ID Number: 359770.  A replay of the webcast will also be available on the corporate website through December 3, 2010.

About NeurogesX, Inc.NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription-strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept, resulting in the commercial launch of Qutenza® (capsaicin) 8% patch in 2010. The Company continues to apply its knowledge and expertise in the development of other novel
'/>"/>

SOURCE NeurogesX
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
4. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
5. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
6. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
7. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
8. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
9. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
10. NeurogesX to Present at JMP Securities Healthcare Focus Conference
11. NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014  Vermillion, Inc. (NASDAQ: VRML ... and women,s health, has appointed Holly B. Bauzon ... Ms. Bauzon has a proven track record ... for laboratory services companies. She has more than 20 ... where she held the position of Director, Lab Services ...
(Date:8/21/2014)... YORK , Aug. 21, 2014  Publicis Groupe ... Shannon Hartley , Managing Partner and Healthcare Industry Group ... PharmaVoice 100, which recognizes the most inspiring people in ... are leaders in research and development, marketing, technology, creativity, ... agency in 2006 as a partner in its leading ...
(Date:8/21/2014)... , Aug. 21, 2014 /PRNewswire-iReach/ -- ... Equipment, Inc. for the third straight year, No. ... 500|5000, an exclusive ranking of the nation,s fastest-growing ... look at the most important segment of the ... Timberland, Dell, Domino,s Pizza, LinkedIn, Zillow, and many ...
Breaking Medicine Technology:Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2Shannon Hartley Shines in PharmaVOICE 100 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3
... Development, LLC (JRD) announced today that the U.S. Food ... designation to the supplemental New Drug Application (sNDA) filed ... an oral anticoagulant, to reduce the risk of thrombotic ... The FDA grants Priority Review to medicines ...
... Feb. 27, 2012 With cold and flu season ... American Pharmacists Association (APhA) encourages patients to actively ... medications. Pharmacists are the most accessible health care provider ... best over-the-counter (OTC) medication for cold, flu and allergy ...
Cached Medicine Technology:U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 2U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 3U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 4U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 5U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 6U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 7U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 8Cold, Flu and Allergy Sufferers Can Select the Best Over-the-Counter Medications with Help from Pharmacists 2Cold, Flu and Allergy Sufferers Can Select the Best Over-the-Counter Medications with Help from Pharmacists 3Cold, Flu and Allergy Sufferers Can Select the Best Over-the-Counter Medications with Help from Pharmacists 4
(Date:8/21/2014)... New York (PRWEB) August 21, 2014 ... Market Research “Home Audio Equipment (Product Types - Home ... audio accessories) Market - Global Industry Analysis, Size, Share, ... was valued at USD 15.94 billion in 2012 and ... growing at a CAGR of 3.7% from 2013 to ...
(Date:8/21/2014)... 21, 2014 The Swedish-American Life ... conference will focus on the Future of Medicine ... innovation and commercialization. , With the mission to ... the worlds' of business and science. "Over the ... Summit, gathering a diverse community with representatives challenging ...
(Date:8/21/2014)... HealthDay Reporter THURSDAY, Aug. ... using sunscreen dropped nearly 12 percent in the last decade, ... the number of teens using indoor tanning beds barely decreased. ... risk of skin cancers, including deadly melanomas, the researchers noted. ... of teens who reported wearing sunscreen, from 67.7 percent in ...
(Date:8/21/2014)... August 21, 2014 The Onder Law ... product liability law, announces the launch of a new ... information on morcellator surgery lawsuits for cancer ... morcellator cancer warning and the July 2014 morcellator recall. ... April 17, 2014 FDA warning on morcellator surgery and ...
(Date:8/21/2014)... announces the immediate release of Care of the ... CHEST Consensus Statement today in the Online First ... the global health-care community cares for patients with ... guide ethical decision-making, coordination of care, resource conservation, ... by over 100 clinicians and experts representing a ...
Breaking Medicine News(10 mins):Health News:Home Audio Equipment Market Expected to Reach USD 20.68 Billion in 2019 2Health News:Home Audio Equipment Market Expected to Reach USD 20.68 Billion in 2019 3Health News:The Tenth Swedish-American Life Science Summit, takingplace in Stockholm, Sweden, August 20-22nd, will focus on The Future of Medicine 2Health News:Fewer U.S. Teens Using Sunscreen, Study Finds 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 3Health News:CHEST releases new expert guidance in care of the critically ill and injured 2
... reporting successful application of the technology used in home ... make anticancer drugs like tamoxifen and paclitaxel dissolve more ... the disease. The process, described in ACS, journal, Langmuir, ... has potential for improving the performance of dyes, paints, ...
... PITTSBURGHUniversity of Pittsburgh researchers have recorded neuron activity ... biological root of the teenage propensity to consider ... more vulnerable to drug addiction, behavioral disorders, and ... the Journal of Neuroscience that electrode ...
... low socioeconomic status (SES) is associated with higher ... arthritis (RA). Statistically significant differences in race, public ... between depressed and non-depressed patients. Study findings are ... Care & Research , a journal published by ...
... 26 (HealthDay News) -- Hispanic seniors in the United ... be vaccinated against flu and pneumonia, a new study ... analyzed data from more than 244,000 seniors who took ... lifetime immunization rates for pneumonia were 74 percent for ...
... Staphylococcus aureus , the bacterium which is responsible for ... a strategy of hiding within host cells to escape ... The research, published by EMBO Molecular Medicine , ... their environmental conditions, lie dormant inside host cells and ...
... to 20 per cent of nurses and nursing students may ... tackling this difficult issue - and protecting public safety - ... message in a paper in the February issue of the ... recommended six key points that could be built into alternative-to-dismissal ...
Cached Medicine News:Health News:Pitt team finds teen brains over-process rewards, suggesting root of risky behavior, mental ills 2Health News:Low socioeconomic status increases depression risk in rheumatoid arthritis patients 2Health News:Research shows how pathogenic bacteria hide inside host cells 2Health News:Support not punishment is the key to tackling substance abuse and addiction among nurses 2Health News:Support not punishment is the key to tackling substance abuse and addiction among nurses 3
The design and concept of the Alpina knee allows the choice of implanting a PCL retaining or a posterior stabilized prosthesis intraoperatively, right up until the definitive implants are to be put i...
Tibial distractor...
... PowerSuite™ holmium laser combines excellent cutting, ... virtually bloodless procedures. It is also ... gall bladder stones of all compositions, ... tool. Because its laser light is ...
... The VersaPulse® PowerSuite™ holmium laser combines ... for precise, virtually bloodless procedures. It ... urinary and gall bladder stones of ... multipurpose surgical tool. Because its laser ...
Medicine Products: